Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.73 |
| ▸ | LTA4H | P09960 | 4/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17826414 | 0.86 | NR5A1 (0.51) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL18773750 | 0.86 | NR5A1 (0.65) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL9394712 | 0.86 | NR5A1 (0.74) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL2675357 | 0.85 | NR5A1 (1.00) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL21054750 | 0.85 | NR5A1 (1.00) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL337505 | 0.85 | NR5A1 (1.00) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1401769 | 0.85 | NR5A1 (1.00) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1835315 | 0.85 | NR5A1 (1.00) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL1834632 | 0.85 | NR5A1 (1.00) | NR5A1LTA4HTP53TSHRPLA2G4B | |
| SCHEMBL337790 | 0.85 | NR5A1 (1.00) | NR5A1LTA4HTP53TSHRPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170306255-A1 | Fuel Markers and Methods of Producing and Using Same | AUTHENTIX, INC. | 2017-10-26 | — | — | US | disclosed |
| US-9732296-B2 | Fuel markers and methods of producing and using same | AUTHENTIX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3070149-B1 | METHOD FOR DETECTING ADULTERATION OF A FUEL | AUTHENTIX INC (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9631152-B2 | Fuel markers and methods of producing and using same | AUTHENTIX, INC. (US) | 2017-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170306255-A1 | Fuel Markers and Methods of Producing and Using Same | CBR1, CBR3, FADS1 | NR5A1 867/4885LTA4H 723/4885TP53 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.